ConductScience.org, home

Trial · NCT03378635

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYTime to Plasma Glucose Recovery0-45 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial productminutesMEDIAN
SECONDARYPlasma Glucose Recovery0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injectionFull analysis set of all randomized patients who received at least one dose of trial productParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPlasma Glucose Changes From Baseline0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injectionFull analysis set of all randomized patients who received at least one dose of trial productmg/dLMEAN
SECONDARYTime to Target0-45 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial productminutesMEDIAN
SECONDARYPharmacodynamics - Area Under the Effect Curve0-30 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial productmg*h/dLMEAN
SECONDARYPharmacokinetics - Area Under the Plasma Concentration Curve0-90 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial product. No results are presented for the placebo group, as no active drug was given in this group.pmol*h/LGEOMETRIC_MEAN
SECONDARYPharmacokinetics - Area Under the Plasma Concentration Curve0-120 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial product. No results are presented for the placebo group, as no active drug was given in this group.pmol*h/LGEOMETRIC_MEAN
SECONDARYPharmacokinetics - Maximum Plasma Concentration0-120 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial product. No results are presented for the placebo group, as no active drug was given in this group.pmol/LGEOMETRIC_MEAN
SECONDARYPharmacokinetics - Time to Maximum Plasma Concentration0-120 minutes after dosingFull analysis set of all randomized patients who received at least one dose of trial product. No results are presented for the placebo group, as no active drug was given in this group.hoursMEDIAN
SECONDARYImmunogenicity - Occurence of Anti-drug Antibodies28 daysThe safety analysis set of all randomized patients who received trial medication (which was the same as the full analysis set)ParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYRescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure0-45 minutes after dosingThe safety analysis set of all randomized patients who received trial medication (which was the same as the full analysis set)ParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYTime to First Rescue Infusion of IV Glucose0-45 minutes after dosingNo patients received IV glucose infusions therefore there are no data available for this outcome measure

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03378635/outcomes